Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Investigators involved in a multicenter study co-led by Cedars-Sinai discovered a pathway by which immune cells prevent the lungs’ protective barrier from healing after viral infections like COVID-19. The findings, published in Nature, may lead to new therapeutic treatment options.
Immune checkpoint inhibitors are a type of cancer treatment that helps the immune system attack cancer cells more effectively. One of the key proteins involved in this process is Lymphocyte Activation Gene-3 (LAG3), which suppresses the antitumor immune response.
WashU Medicine researchers have designed, in mice, an approach to minimizing the damage from a spinal cord injury through the use of engineered immune cells. Mice given the treatment had improved recovery from injuries, demonstrating potential for developing the therapy for people.
PhotonPharma, a pioneering biotech company focused on innovative cancer therapies, is pleased to announce its selection as a premier presenting company in the upcoming Rocky Mountain Life Sciences Investor and Partnering Conference sponsored by the Colorado BioScience Association.
For many doctors and researchers, immunotherapy that uses someone’s own immune system to target and attack cancer cells is the next and best frontier of cancer treatment. Chimeric antigen receptor T-cell therapy, or CAR-T cell therapy, is one type of immunotherapy. Sometimes likened to a “smart drug” or “living drug,” CAR-T cell therapy relies on genetically modified immune cells to recognize and destroy cancer cells.
A computer model developed by UT Southwestern Medical Center researchers significantly enhances the ability of scientists to detect communication between cells, according to a new study published in Nature Methods.
UCLA has received a $120 million commitment from Dr. Gary Michelson and his wife, Alya, to kick-start the California Institute for Immunology and Immunotherapy, an innovative public-private partnership aimed at spurring breakthrough discoveries that prevent and cure diseases and catalyze economic growth and innovation in Los Angeles.
A Ludwig Cancer Research study has identified a metabolic switch in the immune system’s T cells that is essential to the generation of memory T cells—which confer lasting immunity to previously encountered pathogens—and a T cell subtype found in tumors that drives anti-tumor responses during immunotherapy.
Immune cells use two different routes to produce acetyl-CoA, an essential metabolite required to fight infection and cancer, reports a study led by Van Andel Institute scientists.
Scientists at La Jolla Institute for Immunology (LJI) are investigating how the mutated clade 1 mpox virus may affect children and older patients—and how new vaccines can help the body fight back.
In the most comprehensive national study since the onset of the COVID-19 pandemic, a team of researchers that includes a Rutgers-organized consortium of pediatric sites has concluded that long COVID symptoms in children are tangible, pervasive, wide ranging and clinically distinct within specific age groups.
The University of Pennsylvania and the Parker Institute for Cancer Immunotherapy (PICI) have renewed their collaboration to advance cancer immunotherapy research at Penn Medicine’s Abramson Cancer Center (ACC).
The annual influenza vaccination provides updated protection against the virus but could be improved as there is large variability in its efficacy.
The AAI Council is pleased to announce the appointment of Bonnie N. Dittel, Ph.D. (AAI ’00), as the incoming editor-in-chief of ImmunoHorizons (IH).
Rutgers Cancer Institute, the state’s only National Cancer Institute-designated Comprehensive Cancer Center together with RWJBarnabas Health, has treated its 200th patient with CAR T-cell therapy, a type of immunotherapy that uses a patient’s own immune cells to fight cancer.
A novel study led by Prof. Mira Barda-Saad and her research team at the Goodman Faculty of Life Sciences at Bar-Ilan University has unveiled a novel method to rejuvenate natural killer (NK) cells in the fight against cancer. The study, published on the cover of The EMBO Journal, addresses a critical challenge in cancer immunotherapy -- NK cell exhaustion.
Inherited diseases of metabolism and immunity have more in common than previously recognized, according to a new study published in the journal Science Immunology. The findings point to a new set of metabolic genes that are important for the function of immune system T cells, and they offer insights that could improve care for patients with these disorders.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right